Boundless Bio amends Serapha merger deal to add pre-funded warrants, RSU conversion terms

• Boundless Bio plans to merge its Merger Sub into Serapha Bio, leaving Serapha as a wholly owned subsidiary.
• An Aug. 28, 2026 amendment clarified terms tied to Serapha’s pre-closing financing.
• Serapha RSUs will convert into assumed RSUs for Boundless Bio common stock, adjusted by the exchange ratio.
• Merger consideration may include pre-funded warrants at a $0.00001 exercise price to avoid breaching beneficial ownership limits.
• The vote threshold to increase authorized Boundless Bio common shares shifts to a majority of shares cast.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boundless Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-374787), on August 28, 2026, and is solely responsible for the information contained therein.